Aureka Biotechnologies

Aureka Biotechnologies is a private, preclinical-stage biotech company based in San Diego, leveraging an integrated platform of high-throughput synthetic biology, single-cell functional screening, and AI-driven design to discover novel antibody therapeutics. The company is building an internal pipeline targeting cardiometabolic and inflammatory diseases, with a mission to democratize and decentralize drug discovery. As a pre-revenue startup, Aureka's strategy centers on using proprietary data and iterative AI cycles to identify high-value biologics that are difficult to find with conventional methods.

Integrated platform combining high-throughput autonomous evolution, single-cell functional screening, and AI-driven multi-objective/de novo design for protein therapeutic discovery.

Aureka competes in the crowded AI/ML drug discovery sector against companies like AbCellera, Recursion, Generate Biomedicines, and Absci. Its differentiation lies in the tight integration of proprietary high-throughput experimental data generation with its AI models, focusing on a 'function-first' design for antibodies.